DCC-2701: inhibits c-Met protein, TIE-2 protein, and vascular endothelial growth factor receptor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54576299 |
| CHEMBL ID | 3545365 |
| SCHEMBL ID | 139906 |
| MeSH ID | M000605057 |
| Synonym |
|---|
| GNNDEPIMDAZHRQ-UHFFFAOYSA-N |
| n-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| S6412 |
| SCHEMBL139906 |
| CS-3944 |
| n-(4-((2-((cyclopropylcarbonyl)amino)pyridin-4-yl)oxy)-2,5-difluorophenyi)-n-(4- fluorophenyl)cyclopropane-1,1-dicarboxamide |
| altiratinib [usan] |
| dp-5164 |
| unii-t678746713 |
| dcc-2701 |
| altiratinib |
| t678746713 , |
| 1,1-cyclopropanedicarboxamide, n-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)- |
| 1345847-93-9 |
| AC-35383 |
| dcc2701 |
| HY-B0791 |
| altiratinib [inn] |
| altiratinib [who-dd] |
| CHEMBL3545365 |
| 1-n'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| gtpl9174 |
| dcc-270 |
| J-690136 |
| 4-{5-[(e)-2-{4-(2-chlorophenyl)-5-[5-(methylsulfonyl)-2-pyridinyl]-4h-1,2,4-triazol-3-yl}vinyl]-1,3,4-oxadiazol-2-yl}benzonitrile |
| AKOS026750329 |
| altiratinib;dcc2701 |
| EX-A902 |
| mfcd28900672 |
| n-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide |
| D10862 |
| altiratinib (usan) |
| bdbm50193395 |
| 1,1-cyclopropanedicarboxamide, n-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)- |
| altiratinib(dcc-2701) |
| FT-0700171 |
| BCP15682 |
| n-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. |
| F11464 |
| Q27074416 |
| SB18876 |
| NCGC00480913-04 |
| A887875 |
| MS-29472 |
| nsc-784590 |
| nsc784590 |
| A9I , |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 18.5569 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| Interferon beta | Homo sapiens (human) | Potency | 18.5569 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| High affinity nerve growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 0.0009 | 0.0002 | 0.5436 | 10.0000 | AID1318751; AID1533332 |
| Acyl-CoA desaturase 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0027 | 0.0004 | 0.1594 | 1.7100 | AID1421976 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 0.0027 | 0.0004 | 0.3722 | 10.0000 | AID1318734; AID1421976; AID1533349 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.0092 | 0.0000 | 0.4830 | 8.8000 | AID1421977; AID1533346 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0009 | 0.0009 | 0.2094 | 9.0300 | AID1318751 |
| Angiopoietin-1 receptor | Homo sapiens (human) | IC50 (µMol) | 0.0080 | 0.0004 | 0.5553 | 9.0700 | AID1318740; AID1533350 |
| NT-3 growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 0.0046 | 0.0001 | 0.1336 | 1.1150 | AID1318753; AID1533334 |
| BDNF/NT-3 growth factors receptor | Homo sapiens (human) | IC50 (µMol) | 0.0046 | 0.0001 | 0.3352 | 2.9620 | AID1318752; AID1533333 |
| Cysteinyl leukotriene receptor 1 | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 0.0009 | 0.0009 | 0.0880 | 0.5000 | AID1318751 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.61) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||